Accounts Receivable, after Allowance for Credit Loss, Current of Vitro Biopharma, Inc. from 31 Oct 2012 to 31 Oct 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Vitro Biopharma, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 Oct 2012 to 31 Oct 2024.
  • Vitro Biopharma, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 Oct 2024 was $206,292, a 72% increase year-over-year.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Vitro Biopharma, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $206,292 +$86,621 +72% 31 Oct 2024 10-K 28 Jan 2025 2024 FY
Q2 2024 $69,067 -$10,235 -13% 31 Jul 2024 10-Q 16 Sep 2024 2024 Q3
Q1 2024 $157,105 +$109,566 +230% 30 Apr 2024 10-Q 31 May 2024 2024 Q2
Q4 2023 $111,239 +$48,861 +78% 31 Jan 2024 10-Q 14 Mar 2024 2024 Q1
Q3 2023 $119,671 +$46,134 +63% 31 Oct 2023 10-K 28 Jan 2025 2024 FY
Q2 2023 $79,302 31 Jul 2023 10-Q 28 Aug 2023 2023 Q3
Q1 2023 $47,539 30 Apr 2023 10-Q 13 Jun 2023 2023 Q2
Q4 2022 $62,378 31 Jan 2023 10-Q 14 Mar 2023 2023 Q1
Q3 2022 $73,537 31 Oct 2022 10-K 29 Jan 2024 2023 FY
Q4 2012 $2,378 31 Jan 2013 10-Q 21 Mar 2013 2013 Q1
Q3 2012 $2,378 31 Oct 2012 10-K 12 Feb 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.